{
    "id": "0427",
    "question": "A 45-year-old African-American male presents to the family medicine physician to assess the status of his diabetes. After reviewing the laboratory tests, the physician decides to write the patient a prescription for miglitol and states that it must be taken with the first bite of the meal. Which of the following bonds will no longer be cleaved when the patient takes miglitol?",
    "options": {
        "A": "Phosphodiester bonds",
        "B": "Glycosidic bonds",
        "C": "Cystine bonds",
        "D": "Hydrogen bonds"
    },
    "answer": "B",
    "predict": "To answer this question, let's break it down step by step. The patient is prescribed miglitol, which is an \u03b1-glucosidase inhibitor used in the treatment of diabetes. The question asks which type of bond will no longer be cleaved when the patient takes miglitol. Step 1: Understand the mechanism of action of miglitol. Miglitol is an \u03b1-glucosidase inhibitor, which means it works by inhibiting the enzyme \u03b1-glucosidase. This enzyme is responsible for breaking down complex carbohydrates into simpler sugars, specifically breaking the glycosidic bond between glucose molecules. Step 2: Identify the type of bond that miglitol affects. Since miglitol inhibits \u03b1-glucosidase, it targets the glycosidic bond, which is the bond between two carbohydrate molecules. Step 3: Review the options provided to determine which type of bond is not affected by miglitol. - A. Phosphodiester bonds: These bonds are involved in the breakdown of nucleic acids and are not related to carbohydrate digestion. - B. Glycosidic bonds: These bonds are the target of \u03b1-glucosidase inhibitors like miglitol. - C. Cystine bonds: These bonds are found in proteins and are not relevant to carbohydrate digestion. - D. Hydrogen bonds: These bonds are weak electrostatic attractions between molecules and are not specific to carbohydrate digestion. Conclusion: Based on the mechanism of action of miglitol, the correct answer is B. Glycosidic bonds. These bonds will no longer be cleaved when the patient takes miglitol, as the drug inhibits the enzyme that breaks them down. Here is the output in the requested JSON format: {\"step_by_step_thinking\": \"To answer this question, we need to understand the mechanism of action of miglitol, which is an \\u00b1-glucosidase inhibitor. This enzyme breaks down complex carbohydrates into simpler sugars by cleaving the glycosidic bond between glucose molecules. Miglitol works by inhibiting this enzyme, so the glycosidic bond will no longer be cleaved. The correct answer is the type of bond that miglitol affects.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_4629",
            "title": "Pharmacology_Katzung",
            "content": "A 66-year-old obese Caucasian man presented to an academic Diabetes Center for advice regarding his diabetes treatment. His diabetes was diagnosed 10 years previously on routine testing. He was initially given metformin but when his control deteriorated, the metformin was stopped and insulin treatment initiated. The patient was taking 50 units of insulin glargine and an average of 25 units of insulin aspartate pre-meals. He had never seen a diabetes educator or a dietitian. He was checking his glucose levels 4 times a day. He was smoking half a pack of cigarettes a day. On examination, his weight was 132 kg (BMI 39.5); blood pressure 145/71; and signs of mild peripheral neuropathy were present. Laboratory tests noted an HbA1c value of 8.1%, urine albumin 3007 mg/g creatinine (normal <30), serum creatinine 0.86 mg/dL (0.61\u20131.24), total choles-terol 128 mg/dL, triglycerides 86 mg/dL, HDL cholesterol 38 mg/dL, and LDL cholesterol 73 mg/dL (on atorvastatin 40 mg daily). How would you"
        },
        {
            "id": "InternalMed_Harrison_27832",
            "title": "InternalMed_Harrison",
            "content": "The laboratory assessment should first determine whether the patient meets the diagnostic criteria for DM (Table 417-2) and then assess the degree of glycemic control (Chap. 418). In addition to the standard laboratory evaluation, the patient should be screened for DM-associated conditions (e.g., albuminuria, dyslipidemia, thyroid dysfunction). The classification of the type of DM may be facilitated by laboratory assessments. Serum insulin or C-peptide measurements often do not distinguish type 1 from type 2 DM, but a low C-peptide level confirms a patient\u2019s need for insulin. Many individuals with new-onset type 1 DM retain some C-peptide production. Measurement of islet cell antibodies at the time of diabetes onset may be useful if the type of DM is not clear based on the characteristics described above. Diabetes mellitus: management Alvin C. Powers"
        },
        {
            "id": "InternalMed_Harrison_27833",
            "title": "InternalMed_Harrison",
            "content": "Diabetes mellitus: management Alvin C. Powers The goals of therapy for type 1 or type 2 diabetes mellitus (DM) are to (1) eliminate symptoms related to hyperglycemia, (2) reduce or eliminate the long-term microvascular and macrovascular complications of DM (Chap. 419), and (3) allow the patient to achieve as normal a lifestyle as possible. To reach these goals, the physician should identify a target level of glycemic control for each patient, provide the patient with the educational and pharmacologic resources necessary to reach this level, and monitor/treat DM-related complications. Symptoms of diabetes usually resolve when the plasma glucose is <11.1 mmol/L (200 mg/dL), and thus most DM treatment focuses on achieving the second and third goals. This chapter first reviews the ongoing treatment of diabetes in the outpatient setting and then discusses the treatment of severe hyperglycemia, as well as the treatment of diabetes in hospitalized patients."
        },
        {
            "id": "Gynecology_Novak_904",
            "title": "Gynecology_Novak",
            "content": "Table 9.10 Physician Guidelines in the Therapy of Diabetes Mellitus Establish diagnosis and classify type of diabetes mellitus (DM). The oral glucose tolerance test (OGTT) is not recommended for routine clinical use because of its higher cost, time requirement, and limited reproducibility. Initiate diabetes education classes to learn blood glucose monitoring and diabetes medications; to learn signs, symptoms, and complications; and to learn how to manage sick days. Place patient on ADA diet with appropriate caloric, sodium, and lipid restrictions. Establish cardiac risk factors, kidney function (serum creatinine, urine for microalbuminuria). If neuropathy is present, refer to a neurologist. Establish extent of fundoscopic lesion (refer to ophthalmologist as needed). Check feet and toenails at least once a year and refer to a foot specialist. Use finger-stick blood glucose for daily diabetic control. Follow chronic glycemic control by HgA1c every 2 to 3 months in the office."
        },
        {
            "id": "Pharmacology_Katzung_1490",
            "title": "Pharmacology_Katzung",
            "content": "Ramin Sam, MD, Harlan E. Ives, MD, PhD, & David Pearce, MD A 65-year-old man has a history of diabetes and chronic kidney disease with baseline creatinine of 2.2 mg/dL. Despite five different antihypertensive drugs, his clinic blood pres-sure is 176/92 mm Hg; he has mild dyspnea on exertion and 2\u20133+ edema on exam. He has been taking furosemide 80 mg twice a day for 1 year now. At the clinic visit, hydrochlorothi-azide 25 mg daily is added for better blood pressure control and also to treat symptoms and signs of fluid overload. Two weeks later, the patient presents to the emergency depart-ment with symptoms of weakness, anorexia, and generalized malaise. His blood pressure is now 91/58 mm Hg, and he has lost 15 kg in 2 weeks. His laboratory tests are signifi-cant for a serum creatinine of 10.8 mg/dL. What has led to the acute kidney injury? What is the reason for the weight loss? What precautions could have been taken to avoid this hospitalization?"
        },
        {
            "id": "InternalMed_Harrison_27859",
            "title": "InternalMed_Harrison",
            "content": "Diabetes Mellitus: Management and Therapies 2410 DM or individuals with type 2 DM taking multiple insulin injections each day should routinely measure their plasma glucose three or more times per day to estimate and select mealtime boluses of short-acting insulin and to modify long-acting insulin doses. Most individuals with type 2 DM require less frequent monitoring, although the optimal frequency of SMBG has not been clearly defined. Individuals with type 2 DM who are taking insulin should use SMBG more frequently than those on oral agents. Individuals with type 2 DM who are on oral medications should use SMBG as a means of assessing the efficacy of their medication and the impact of diet. Because plasma glucose levels fluctuate less in these individuals, one to two SMBG measurements per day (or fewer in patients who are on oral agents or are diet-controlled) may be sufficient. Most measurements in individuals with type 1 or type 2 DM should be performed prior to a meal and"
        },
        {
            "id": "Biochemistry_Lippincott_309",
            "title": "Biochemistry_Lippinco",
            "content": ".4. Why are \u03b1-glucosidase inhibitors that are taken with meals, such as acarbose and miglitol, used in the treatment of diabetes? What effect should these drugs have on the digestion of lactose? \u03b1-Glucosidase inhibitors slow the production of glucose from dietary carbohydrates, thereby reducing the postprandial rise in blood glucose and facilitating better blood glucose control in diabetic patients. These drugs have no effect on lactose digestion because the disaccharide lactose contains a \u03b2glycosidic bond, not an \u03b1-glycosidic bond. Introduction to Metabolism and Glycolysis 8 For additional ancillary materials related to this chapter, please visit thePoint. I. METABOLISM OVERVIEW"
        },
        {
            "id": "Pharmacology_Katzung_4332",
            "title": "Pharmacology_Katzung",
            "content": "George P. Chrousos, MD A 19-year-old man complains of anorexia, fatigue, dizziness, and weight loss of 8 months\u2019 duration. The examining physician discovers postural hypotension and moderate vitiligo (depigmented areas of skin) and obtains routine blood tests. She finds hyponatremia, hyperkalemia, and acidosis and suspects Addison\u2019s disease. She performs a standard ACTH 1\u201324 stimulation test, which reveals an insufficient plasma cortisol response compatible with primary adrenal insuf-ficiency. The diagnosis of autoimmune Addison\u2019s disease is made, and the patient must start replacement of the hormones he cannot produce himself. How should this patient be treated? What precautions should he take?"
        },
        {
            "id": "Biochemistry_Lippincott_1244",
            "title": "Biochemistry_Lippinco",
            "content": "Choose the ONE best answer. For Questions 26.1 and 26.2, use the following scenario. A 40-year-old woman, 5 ft, 1 in (155 cm) tall and weighing 188 lb (85.5 kg), seeks your advice on how to lose weight. Her waist measured 41 in and her hips 39 in. The remainder of the physical examination and the blood laboratory data were all within the normal range. Her only child (who is age 14 years), her sister, and both of her parents are overweight. The patient recalls being overweight throughout her childhood and adolescence. Over the past 15 years, she had been on seven different diets for periods of 2 weeks to 3 months, losing from 5 to 25 lb each time. On discontinuation of the diets, she regained weight, returning to 185\u2013190 lb. 6.1. Calculate and interpret the body mass index for the patient. Body mass index (BMI) = weight in kg/(height in m)2 = 85.5/1.552 = 35.6. Because her BMI is >30, the patient is classified as obese."
        },
        {
            "id": "Biochemistry_Lippincott_80",
            "title": "Biochemistry_Lippinco",
            "content": "B. It may be found in typical globular proteins. C. It is stabilized by interchain hydrogen bonds. D. It is an example of secondary structure. E. It may be found in supersecondary structures. Correct answer = C. The \u03b2-sheet is stabilized by interchain hydrogen bonds formed between separate polypeptide chains and by intrachain hydrogen bonds formed between regions of a single polypeptide. The \u03b1-helix, however, is stabilized only by intrachain hydrogen bonds. Statements A, B, D, and E are true for both of these secondary structural elements. .4. An 80-year-old man presented with impairment of intellectual function and alterations in behavior. His family reported progressive disorientation and memory loss over the last 6 months. There is no family history of dementia. The patient was tentatively diagnosed with Alzheimer disease (AD). Which one of the following best describes AD? A. It is associated with \u03b2-amyloid, an abnormal protein with an altered amino acid sequence."
        },
        {
            "id": "Pharmacology_Katzung_1764",
            "title": "Pharmacology_Katzung",
            "content": "During a routine check and on two follow-up visits, a 45-year-old man was found to have high blood pressure (160\u2013165/95\u2013100 mm Hg). His physician initially prescribed hydrochlorothiazide, a diuretic commonly used to treat hyper-tension. His blood pressure was reduced by hydrochloro-thiazide but remained at a hypertensive level (145/95 mm Hg), and he was referred to the university hypertension clinic. Because the patient had elevated plasma renin activity and aldosterone concentration, hydrochlorothiazide was replaced with enalapril, an angiotensin-converting enzyme inhibitor. Enalapril lowered his blood pressure to almost normotensive levels. However, after several weeks on enalapril, the patient returned complaining of a persistent cough. In addition, some signs of angioedema were detected. How does enalapril lower blood pressure? Why does it occasionally cause coughing and angioedema? What other drugs could be used to inhibit the renin-angiotensin system and decrease blood pressure,"
        },
        {
            "id": "InternalMed_Harrison_27823",
            "title": "InternalMed_Harrison",
            "content": "APPROACH TO THE PATIENT: Once the diagnosis of DM is made, attention should be directed to symptoms related to diabetes (acute and chronic) and classifying the type of diabetes. DM and its complications produce a wide range of symptoms and signs; those secondary to acute hyperglycemia may occur at any stage of the disease, whereas those related to chronic hyperglycemia begin to appear during the second decade of hyperglycemia (Chap. 419). Individuals with previously undetected type 2 DM may present with chronic complications of DM at the time of diagnosis. The history and physical examination should assess for symptoms or signs of acute hyperglycemia and should screen for the chronic complications and conditions associated with DM."
        },
        {
            "id": "First_Aid_Step2_1232",
            "title": "First_Aid_Step2",
            "content": "When treatment noncompliance represents a serious danger to public health (e.g., active TB). Treat because the disease represents an immediate threat to the child\u2019s life. Then seek a court order. A physician can withhold information from the patient only in the rare case of therapeutic privilege or if the patient requests not to be told. A patient\u2019s family cannot require the physician to withhold information from the patient. Diagnostic modality used when ultrasound is equivocal for cholecystitis. Risk factors for cholelithiasis. Inspiratory arrest during palpation of the RUQ. The most common cause of SBO in patients with no history of abdominal surgery. The most common cause of SBO in patients with a history of abdominal surgery. Identify key organisms causing diarrhea: A 25-year-old Jewish man presents with pain and watery diarrhea after meals. Exam shows fistulas between the bowel and skin and nodular lesions on his tibias."
        },
        {
            "id": "Pharmacology_Katzung_5118",
            "title": "Pharmacology_Katzung",
            "content": "A 45-year-old man with no significant medical history was admitted to the intensive care unit (ICU) 10 days ago after suffering third-degree burns over 40% of his body. He had been relatively stable until the last 24 hours. Now, he is febrile (39.5\u00b0C [103.1\u00b0F]), and his white blood cell count has risen from 8500 to 20,000/mm3. He has also had an episode of hypo-tension (86/50 mmHg) that responded to a fluid bolus. Blood cultures were obtained at the time of his fever and results are pending. The ICU attending physician is concerned about a bloodstream infection and decides to treat with empiric com-bination therapy directed against Pseudomonas aeruginosa. The combination therapy includes tobramycin. The patient weighs 70 kg (154 lb) and has an estimated creatinine clear-ance of 90 mL/min. How should tobramycin be dosed using once-daily and conventional dosing strategies? How should each regimen be monitored for efficacy and toxicity?"
        },
        {
            "id": "InternalMed_Harrison_27865",
            "title": "InternalMed_Harrison",
            "content": "Comprehensive care of type 1 and type 2 DM requires an emphasis on nutrition, exercise, and monitoring of glycemic control but also usually involves glucose-lowering medication(s). This chapter discusses classes of such medications but does not describe every glucose-lowering agent available worldwide. The initial step is to select an individualized, glycemic goal for the patient. Because the complications of DM are related to glycemic control, normoglycemia or near-normoglycemia is the desired, but often elusive, goal for most patients. Normalization or near-normalization of the plasma glucose for long periods of time is extremely difficult, as demonstrated by the DCCT and United Kingdom Prospective Diabetes Study (UKPDS). Regardless of the level of hyperglycemia, improvement in glycemic control will lower the risk of diabetes-specific complications (Chap. 419)."
        },
        {
            "id": "First_Aid_Step2_1230",
            "title": "First_Aid_Step2",
            "content": "Involuntary psychiatric hospitalization can be undertaken for which three reasons? True or false: Withdrawing a nonbeneficial treatment is ethically similar to withholding a nonindicated one. When can a physician refuse to continue treating a patient on the grounds of futility? An eight-year-old child is in a serious accident. She requires emergent transfusion, but her parents are not present. Conditions in which confidentiality must be overridden. Involuntary commitment or isolation for medical treatment may be undertaken for what reason? A 10-year-old child presents in status epilepticus, but her parents refuse treatment on religious grounds. A son asks that his mother not be told about her recently discovered cancer. False. Patients may change their minds at any time. Exceptions to the requirement of informed consent include emergency situations and patients without decision-making capacity."
        },
        {
            "id": "First_Aid_Step2_171",
            "title": "First_Aid_Step2",
            "content": "Associated with HLA-DR3 and -DR4. At least one of the following is required to make the diagnosis: A fasting (> 8-hour) plasma glucose of \u2265 126 mg/dL on two separate occasions. A random plasma glucose of \u2265 200 mg/dL plus symptoms. A two-hour postprandial glucose of \u2265 200 mg/dL after a glucose tolerance test on two separate occasions if the results of initial testing are equivocal. Insulin (see Table 2.3-1) and self-monitoring of blood glucose in the normal range (80\u2013120 mg/dL). Higher blood glucose levels (\u2265 200 mg/dL) can be tolerated, particularly in the very young, in light of the \u2191 risk of hypoglycemia. Routine HbA1c testing (with a goal HbA1c < 8 in children), frequent BP checks, foot checks, annual dilated-eye exams, annual microalbuminuria screening, and a lipid profile every 2\u20135 years. TABLE 2.3-1. Types of Insulin"
        },
        {
            "id": "Anatomy_Gray_578",
            "title": "Anatomy_Gray",
            "content": "Similarly the dissection can impair blood flow to the kidneys, which decreases their ability to function. The patient underwent emergency surgery and survived. Interestingly, the height of the patient and the previous lens surgery would suggest a diagnosis of Marfan syndrome, and a series of blood tests and review of the family history revealed this was so. A 35-year-old male patient presented to his family practitioner because of recent weight loss (14 lb over the previous 2 months). He also complained of a cough with streaks of blood in the sputum (hemoptysis) and left-sided chest pain. Recently, he noticed significant sweating, especially at night, which necessitated changing his sheets."
        },
        {
            "id": "First_Aid_Step2_1261",
            "title": "First_Aid_Step2",
            "content": "A 13-year-old boy has a history of theft, vandalism, and violence toward family pets. A five-month-old girl has \u2193 head growth, truncal dyscoordination, and \u2193 social interaction. A patient hasn\u2019t slept for days, lost $20,000 gambling, is agitated, and has pressured speech. Diagnosis? Treatment? After a minor fender bender, a man wears a neck brace and requests permanent disability. A nurse presents with severe hypoglycemia; blood analysis reveals no elevation in C-peptide. A patient continues to use cocaine after being in jail, losing his job, and not paying child support. A violent patient has vertical and horizontal nystagmus. A woman who was abused as a child frequently feels outside of or detached from her body. A man has repeated, intense urges to rub his body against unsuspecting passengers on a bus. A schizophrenic patient takes haloperidol for one year and develops uncontrollable tongue movements. Diagnosis? Treatment?"
        },
        {
            "id": "Pharmacology_Katzung_4656",
            "title": "Pharmacology_Katzung",
            "content": "If the fasting plasma glucose level is less than 126 mg/dL (7 mMol/L) but diabetes is nonetheless suspected, then a standardized oral glucose tolerance test may be done (Table 41\u20134). The patient should eat nothing after midnight prior to the test day. On the morning of the test, adults are then given 75 g of glucose in 300 mL of water; children are given 1.75 g of glucose per kilogram of ideal body weight. The glucose load is consumed within 5 minutes. Blood samples for plasma glucose are obtained at 0 and 120 minutes after ingestion of glucose. An oral glucose tolerance test is normal if the fasting venous plasma glucose value is less than 100 mg/dL (5.6 mmol/L) and the 2-hour value falls below 140 mg/dL (7.8 mmol/L). A fasting value of 126 mg/dL (7 mmol/L) or higher or a 2-hour value of greater than 200 mg/dL (11.1 mmol/L) is diagnostic of diabetes mellitus. Patients with 2-hour value of 140\u2013199 mg/dL (7.8\u201311.1 mmol/L) have impaired glucose tolerance."
        },
        {
            "id": "InternalMed_Harrison_27849",
            "title": "InternalMed_Harrison",
            "content": "The goal of MNT in the individual with type 1 DM is to coordinate and match the caloric intake, both temporally and quantitatively, with the appropriate amount of insulin. MNT in type 1 DM and self-monitoring of blood glucose must be integrated to define the optimal insulin regimen. The ADA encourages patients and providers to use carbohydrate counting or exchange systems to estimate the nutrient content of a meal or snack. Based on the patient\u2019s estimate of the carbohydrate content of a meal, an insulin-to-carbohydrate ratio determines the bolus insulin dose for a meal or snack. MNT must be flexible enough to allow for exercise, and the insulin regimen must allow for deviations in caloric intake. An important component of MNT in type 1 DM is to minimize the weight gain often associated with intensive diabetes management."
        },
        {
            "id": "InternalMed_Harrison_27764",
            "title": "InternalMed_Harrison",
            "content": "The diagnosis of DM has profound implications for an individual from both a medical and a financial standpoint. Thus, abnormalities on screening tests for diabetes should be repeated before making a definitive diagnosis of DM, unless acute metabolic derangements or a markedly elevated plasma glucose are present (Table 417-2). These criteria also allow for the diagnosis of DM to be withdrawn in situations when the glucose intolerance reverts to normal."
        },
        {
            "id": "InternalMed_Harrison_28112",
            "title": "InternalMed_Harrison",
            "content": "The diagnostic strategy is (1) to measure plasma glucose, insulin, C-peptide, proinsulin, and \u03b2-hydroxybutyrate concentrations and to screen for circulating oral hypoglycemic agents during an episode of hypoglycemia and (2) to assess symptoms during the episode and seek their resolution following correction of hypoglycemia by IV injection of glucagon (i.e., to document Whipple\u2019s triad). This is straightforward if the patient is hypoglycemic when seen. Since endogenous hyperinsulinemic disorders usually, but not invariably, cause fasting hypoglycemia, a diagnostic episode may develop after a relatively short outpatient fast. Serial sampling during an inpatient diagnostic fast of up to 72 h or after a mixed meal is more problematic. An alternative is to give patients a detailed list of the required measurements and ask them to present to an emergency room, with the list, during a symptomatic episode. Obviously, a normal plasma glucose concentration during a symptomatic episode indicates"
        },
        {
            "id": "Pharmacology_Katzung_4719",
            "title": "Pharmacology_Katzung",
            "content": "Acarbose has the molecular mass and structural features of a tet rasaccharide and very little is absorbed. In contrast, miglitol has structural similarity to glucose and is absorbed. Acarbose treatment is initiated at a dosage of 50 mg twice daily with gradual increase to 100 mg three times a day. It lowers post prandial glucose levels by 30\u201350%. Miglitol therapy is initiated at a dosage of 25 mg three times a day. The usual maintenance dosage is 50 mg three times a day, but some patients may need 100 mg three times a day. The drug is not metabolized and is cleared by the kidney. It should not be used in renal failure."
        },
        {
            "id": "Pediatrics_Nelson_3549",
            "title": "Pediatrics_Nelson",
            "content": "Serum glucose concentrations should be assessed before each meal, at bedtime, and periodically at 2 to 3 am to provide information for adjustment of the regimen. Patients and their families should begin learning the principles of diabetes care as soon as possible. Demonstration of the ability to administer insulin injections and test glucose concentrations using a glucose meter is necessary before discharge, as is knowledge of hypoglycemia management. Meal planning is crucial to control glucose in DM1. Nutrition services must be part of the care delivered to the families from diagnosis."
        },
        {
            "id": "InternalMed_Harrison_27739",
            "title": "InternalMed_Harrison",
            "content": "DM is classified on the basis of the pathogenic process that leads to hyperglycemia, as opposed to earlier criteria such as age of onset or type of therapy (Fig. 417-1). There are two broad categories of DM, designated type 1 and type 2 (Table 417-1). However, there is increasing recognition of other forms of diabetes in which the pathogenesis is better understood. These other forms of diabetes may share features of Type of <5.6 mmol/L 5.6\u20136.9 mmol/L \u02dc7.0 mmol/L (100 mg/dL) 2-h PG <7.8 mmol/L 7.8\u201311.0 mmol/L \u02dc11.1 mmol/L (140 mg/dL) HbA1C <5.6% 5.7\u20136.4% \u02dc6.5%"
        },
        {
            "id": "InternalMed_Harrison_27917",
            "title": "InternalMed_Harrison",
            "content": "Diabetes Mellitus: Management and Therapies 2416 Because endogenous insulin secretion continues and is capable of providing some coverage of mealtime caloric intake, insulin is usually initiated in a single dose of long-acting insulin (0.3\u20130.4 U/kg per day), given in the evening (NPH) or just before bedtime (NPH, glargine, detemir). Because fasting hyperglycemia and increased hepatic glucose production are prominent features of type 2 DM, bedtime insulin is more effective in clinical trials than a single dose of morning insulin. Glargine given at bedtime has less nocturnal hypoglycemia than NPH insulin. Some physicians prefer a relatively low, fixed starting dose of long-acting insulin (5\u201315 units) or a weight-based dose (0.2 units/kg). The insulin dose may then be adjusted in 10% increments as dictated by SMBG results. Both morning and bedtime long-acting insulin may be used in combination with oral glucose-lowering agents. Initially, basal insulin may be sufficient, but often"
        },
        {
            "id": "InternalMed_Harrison_27936",
            "title": "InternalMed_Harrison",
            "content": "Individuals with type 1 or type 2 DM and severe hyperglycemia (>16.7 mmol/L [300 mg/dL]) should be assessed for clinical stability, including mentation and hydration. Depending on the patient and the rapidity and duration of the severe hyperglycemia, an individual may require more intense and rapid therapy to lower the blood glucose. However, many patients with poorly controlled diabetes and hyperglycemia have few symptoms. The physician should assess if the patient is stable or if diabetic ketoacidosis or a hyperglycemic hyperosmolar state should be considered. Ketones, an indicator of diabetic ketoacidosis, should be measured in individuals with type 1 DM when the plasma glucose is >16.7 mmol/L (300 mg/dL), during a concurrent illness, or with symptoms such as nausea, vomiting, or abdominal pain. Blood measurement of \u03b2-hydroxybutyrate is preferred over urine testing with nitroprusside-based assays that measure only acetoacetate and acetone."
        },
        {
            "id": "InternalMed_Harrison_27835",
            "title": "InternalMed_Harrison",
            "content": "A number of names are sometimes applied to different approaches to diabetes care, such as intensive insulin therapy, intensive glycemic control, and \u201ctight control.\u201d The current chapter, and other sources, uses the term comprehensive diabetes care to emphasize the fact that optimal diabetes therapy involves more than plasma glucose management and medications. Although glycemic control is central to optimal diabetes therapy, comprehensive diabetes care of both type 1 and type 2 DM should also detect and manage DM-specific complications (Chap. 419) and modify risk factors for DM-associated diseases. The key elements of comprehensive diabetes care are summarized in Table 418-1. In addition to the physical aspects of DM, social, family, financial, cultural, and employment-related issues may impact diabetes care. The International Diabetes Federation (IDF), recognizing that resources available for diabetes care vary widely throughout the world, has issued guidelines for \u201crecommended care\u201d"
        },
        {
            "id": "Gynecology_Novak_906",
            "title": "Gynecology_Novak",
            "content": "If the HgA1C is <7% or the postprandial glucose is <200 mg/dL, omit the oral hypoglycemic agents, place on diet alone, and follow every 3 months. If the fasting serum glucose is >200 mg/dL consistently or the HgA1C is more than 10%, consider starting insulin and referring the patient to an internist. Administer the \ufb02u vaccine every fall and the pneumococcal vaccine every 6 years. ADA, American Diabetic Association; HgA1c, hemoglobin A1C; CBC, complete blood count; ECG, electrocardiogram. Adapted from The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000;23:S4\u2013S42. Table 9.11 Patient Guidelines for Treatment of Type 2 Diabetes Initiate an ADA reducing diet (50% CHO, 30% fat, 20% protein, high fiber) with three meals a day. Maintain ideal body weight or to reduce weight by 5% to 15% in 3 months if obese."
        },
        {
            "id": "InternalMed_Harrison_27919",
            "title": "InternalMed_Harrison",
            "content": "cHoice of initial GlucoSe-loWerinG aGent The level of hyperglycemia and the patient\u2019s individualized goal (see \u201cEstablishment of Target Level of Glycemic Control\u201d) should influence the initial choice of therapy. Assuming that maximal benefit of MNT and increased physical activity has been realized, patients with mild to moderate hyperglycemia (FPG <11.1\u201313.9 mmol/L [200\u2013250 mg/dL]) often respond well to a single, oral glucose-lowering agent. Patients with more severe hyperglycemia (FPG >13.9 mmol/L [250 mg/dL]) may respond partially but are unlikely to achieve normoglycemia with oral monotherapy. A stepwise approach that starts with a single agent and adds a second agent to achieve the glycemic target can be used (see \u201cCombination therapy with glucose-lowering agents,\u201d below). Insulin can be used as initial therapy in individuals with severe hyperglycemia (FPG <13.9\u201316.7 mmol/L [250\u2013300 mg/dL]) or in those who are symptomatic from the hyperglycemia. This approach is based on the"
        },
        {
            "id": "First_Aid_Step2_241",
            "title": "First_Aid_Step2",
            "content": "Precontemplation Denial or ignorance of the problem. A 51-year-old smoker has not even thought about cessation. Contemplation Ambivalence or con\ufb02icted emotions; assessing benefits and barriers to change. A 43-year-old crack cocaine addict considers treatment for her addiction. Preparation Experimenting with small changes; collecting information about change. A 28-year-old heroin addict visits his doctor to ask questions about quitting. Taking direct action toward achieving a goal. A 33-year-old enters a rehabilitation facility for treatment of addiction to prescription narcotics. Maintaining a new behavior; avoiding temptation. A 41-year-old continues to visit Alcoholics Anonymous meetings to gain support and reinforcement against relapse. Action Maintenance \u25a0Live vaccines should not be administered to immunosuppressed patients. Such vaccines are also contraindicated in pregnant women owing to a theoretical risk of maternal-fetal transmission."
        }
    ],
    "scores": [
        0.03691671507205488,
        0.0210826009397842,
        0.018605053651782624,
        0.017252918866661707,
        0.01711081986311344,
        0.017022792022792024,
        0.016998166172943998,
        0.01624468557649597,
        0.015960156435816455,
        0.015924741760944418,
        0.015756302521008403,
        0.01568133691981915,
        0.015371762740183793,
        0.015229885057471264,
        0.015056664867781976,
        0.014840299887028858,
        0.014646464646464647,
        0.014585883312933496,
        0.014190356159268076,
        0.014140562813129184,
        0.014124293785310734,
        0.014059514059514059,
        0.014003133568350961,
        0.013813953488372093,
        0.013804554079696395,
        0.013628383997043334,
        0.013461369814960975,
        0.013351360486733143,
        0.012404870624048707,
        0.011636901758988329,
        0.011369426751592356,
        0.011343302658486707
    ]
}